The transcatheter mitral valve replacement (TMVR) market is projected to grow at a CAGR of 20% over the forecast period. Major factors driving growth include increased prevalence of mitral valve ...
Most devicemakers aiming to provide a treatment for mitral regurgitation—see Abbott, Medtronic, InnovHeart and more—are doing so by developing implants that are placed directly within a faulty mitral ...
In this month alone, Edwards Lifesciences and Abbott have made deals with three mitral valve disease startups underscoring the possibility of a M&A flurry in this market. Arundhati Parmar Now that the ...
Livanova plc of London has concluded the PRELUDE study, a 20-patient feasibility study of the Caisson transcatheter mitral valve replacement (TMVR) device the company acquired in 2017. The company ...
UPMC Heart and Vascular Institute in Central Pa. today announced that its doctors treated a patient using the Half Moon Medical transcatheter mitral repair technology (Half Moon TMVr System). This ...
- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology - MitraClip is a first-of-its-kind ...
(UPDATED) To help manage thrombotic risk after transcatheter mitral valve replacement (TMVR), clinicians should consider routine use of oral anticoagulation and regular clinical and imaging follow-up, ...
Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.
TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid ...
Innovheart srl has landed more than $55 million to continue clinical trials of its transcatheter mitral valve replacement (TMVR) system for the treatment of mitral valve disease. The series C equity ...
Abbott Laboratories has received approval for a mitral valve replacement that can be implanted without open-heart surgery. The U.S. Food & Drug Administration gave the OK for the North Chicago-based ...
SAN FRANCISCO, CA—Earlier results from the COAPT trial have established that use of a MitraClip (Abbott) on top of guideline-directed medical therapy (GDMT) cuts mortality and heart failure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback